commerciallyAbiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F24%3A10001242" target="_blank" >RIV/00064190:_____/24:10001242 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.5603/rpor.99028" target="_blank" >https://doi.org/10.5603/rpor.99028</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5603/rpor.99028" target="_blank" >10.5603/rpor.99028</a>

Jazyk výsledku

angličtina

Název v původním jazyce

commerciallyAbiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer

Popis výsledku v původním jazyce

Background: The aim was to assess therapeutic outcomes and tolerance in patients with metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor targeted agents (ARTA) treatment at one oncological center in the Czech Republic. Materials and methods: Retrospective analysis of 64 patients with mCRPC treated with abiraterone (50 patients) and enzalutamide (14 patients) in the first line of this disease was conducted. Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. Results: The median follow-up was 28.4 months. The median PFS was 15.4 months [95% confidence interval (CI): 12.3-18.5], median OS was 38.2 months (95% CI: 19.9-56.5). Regression analysis demonstrated a favorable prognostic effect on PFS in patients with reduction of PSA GREATER-THAN OR EQUAL TO 50 %, in patients with early reduction of prostate-specific antigen (PSA) GREATER-THAN OR EQUAL TO 50% within 3 months, in patients younger than 74 years and in overall performance status (PS) 0. Regression analysis demonstrated a favorable prognostic effect on OS in patients with reduction of PSA GREATER-THAN OR EQUAL TO 50 %, in patients with early reduction of PSA GREATER-THAN OR EQUAL TO 50 % within 3 months and in patients with overall PS 0. Adverse effects grade 3-4 were reported in 17 (27.9%) patients in abirateron arm and in 1 (7.1%) patient in enzalutamide arm. Conclusion: The analysis of patients with mCRPC treated with ARTA in the first line showed that ARTA represents an effective and safe therapy and contributes to longer survival. (C) 2024 Greater Poland Cancer Centre.

Název v anglickém jazyce

commerciallyAbiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer

Popis výsledku anglicky

Background: The aim was to assess therapeutic outcomes and tolerance in patients with metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor targeted agents (ARTA) treatment at one oncological center in the Czech Republic. Materials and methods: Retrospective analysis of 64 patients with mCRPC treated with abiraterone (50 patients) and enzalutamide (14 patients) in the first line of this disease was conducted. Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. Results: The median follow-up was 28.4 months. The median PFS was 15.4 months [95% confidence interval (CI): 12.3-18.5], median OS was 38.2 months (95% CI: 19.9-56.5). Regression analysis demonstrated a favorable prognostic effect on PFS in patients with reduction of PSA GREATER-THAN OR EQUAL TO 50 %, in patients with early reduction of prostate-specific antigen (PSA) GREATER-THAN OR EQUAL TO 50% within 3 months, in patients younger than 74 years and in overall performance status (PS) 0. Regression analysis demonstrated a favorable prognostic effect on OS in patients with reduction of PSA GREATER-THAN OR EQUAL TO 50 %, in patients with early reduction of PSA GREATER-THAN OR EQUAL TO 50 % within 3 months and in patients with overall PS 0. Adverse effects grade 3-4 were reported in 17 (27.9%) patients in abirateron arm and in 1 (7.1%) patient in enzalutamide arm. Conclusion: The analysis of patients with mCRPC treated with ARTA in the first line showed that ARTA represents an effective and safe therapy and contributes to longer survival. (C) 2024 Greater Poland Cancer Centre.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Reports of Practical Oncology and Radiotherapy

ISSN

1507-1367

e-ISSN

—

Svazek periodika

29

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

9

Strana od-do

1-9

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85188792331